USV will launch Vibact IBS based on the probiotic formulation Probi Digestis, in Q4 2012 in the growing Indian market. The agreement reinforces and strengthens Probi’s existing presence in the large Indian market.
Michael Oredsson, CEO of Probi, said: “USV is the best probiotic partner in the consumer healthcare sector in India. We are very pleased to partner with USV and to be able to launch our probiotic formulation Probi Digestis in a market with significant growth potential.”
Probi’s capsules based on the Lactobacillus plantarum 299v strain will be launched under the Vibact IBS brand and will feature Probi’s logo and ingredient prominently on the pack. Vibact IBS will specifically target IBS symptoms like bloating, flatulence and pain. These are symptoms which are common in the Indian population.
Probi’s partner Institut Rosell’s current distribution agreements in India covering Lp299v capsules with Aristo Pharmaceuticals and Ranbaxy will remain in force but limited overlap is expected.
Source: Probi
© FoodBev Media Ltd 2024